Pharmaceutical Grade CAS 105628-07-7 Fasudil Hydrochloride Raw Fasudil Hydrochloride Powder Fasudil Hydrochloride

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: Powder
• Purity: >99%
• Model NO.: D-sung Fasudil hydrochloride
• Product Name: Fasudil Hydrochloride
• Name: Fasudil Hydrochloride Powder
• Appearance: White Powder
• Color: White
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Pharmaceutical
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 105628-07-7
• Mf: C14h18cln3o2s
• MW: 327.83
• Melting Point: 220.5
• Boiling Point: 506.2
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 1000kg/Month

Product Description

Pharmaceutical Grade CAS 105628-07-7 Fasudil hydrochloride Raw Fasudil hydrochloride Powder Fasudil hydrochloride

Product Description

Product Details

Product Name	Fasudil Hcl
CAS	105628-07-7
Appearance	White crystalline powder
MF	C14H18ClN3O2S
MW	327.827
Purity	99%
Shelf Life	2 Years

Fasudil hydrochloride, a novel calcium antagonistic vasodilator, was marketed for the treatment of cerebral vasospasm following subarachnoid hemorrhage (SAH). Fasudil is also a potent inhibitor of myosin light chain kinase and protein kinase C. In contrast to other calcium channel blockers, which regulate the influx of calcium ions through the cell membrane but not involved in the intracellular regulatory mechanism of the calcium, fasudil was suggested to have an intracellular mode of action in relaxing vascular smooth muscle. In patients with neurological deficits due to vasospasm, fasudil decreased the occurrence of angiographic severe and symptomatic vasospasm and cerebral infarction without decreasing systemic blood pressure. Fasudil is reportedly in clinical trials for acute ischemic stroke, sequelae of cerebral vascular diseases and angina pectoris.

Application&Function

Function
Fasudil hydrochloride can promote the recovery of nerve function, relieve clinical symptoms and reduce the rate of disability. Therefore, ultra-early thrombolytic therapy can not be realized at the grass-roots level due to the restriction of economic conditions and awareness of diseases. However, in order to reduce the further progress of diseases, it is very important to reconstruct local blood circulation within the treatment time window. Fasudil hydrochloride has significant neuroprotective and therapeutic effects on ischemic cerebrovascular diseases, which is worthy of clinical use, especially at the grass-roots level, to reduce the disability rate and improve the quality of life.
Application
Fasudil Hydrochloride is a new drug with a wide range of pharmacological effects, developed by Asahi Kasei Corporation (Japan.) It is a cardiovascular and cerebrovascular drug which improves symptoms of ischemic cerebrovascular disease such as cerebral vasospasm following subarachnoid hemorrhage. It has significant neuroprotective and therapeutic effects for ischemic cerebrovascular disease, and is suited for clinical use, particularly at the grassroots level to reduce mortality and improve quality of life.

Specification